Ƶ

Diabetes Drugs Overpriced; Hormone Drugs and Brain Tumors; Menopause or Herpes?

— News and commentary from the endocrinology world

Ƶ MedicalToday
Endo Break over a computer rendering of a man with illustrated body organs.

Insulins, SGLT2 inhibitors, and GLP-1 receptor agonists for prices "far below" their current prices, according to an economic evaluation of manufacturing costs in JAMA Network Open.

In related news, for its customers to include semaglutide (Ozempic). (USA Today)

Prolonged use of -- widely used for endometriosis and polycystic ovary syndrome (PCOS) -- was associated with an increased risk of intracranial meningioma brain tumors in a French population-based study. (BMJ)

Here's why PCOS still lacks a after nearly a century. (NBC News)

The novel GLP-1/glucagon dual receptor agonist pemvidutide yielded a mean weight loss of 15.6% at week 48 with 74.5% of weight loss from adipose tissue, according to more data from the phase II . Developer Altimmune said that was comparable to compositional changes from diet and exercise.

There was statistically significant prolongation of the mean QTc interval by 19.1 ms over 6 months in a trial of transgender women and nonbinary or transfeminine individuals starting . (JAMA Network Open)

Actress was initially misdiagnosed as herpes. (Los Angeles Times)

Greater exposure to the flame retardant polybrominated diphenyl ether (PBDE) -- a type of endocrine-disrupting chemical -- was linked with an over 17-year follow-up of more than 16,000 U.S. adults. (JAMA Network Open)

More Americans are adopting when discussing weight. (Axios)

The trail of people reached another Pittsburgh-area care home. (CBS News)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.